Payment overview · 2025
General Payments
$582.46
44 reported records · 13 companies
Healthcare provider profile · identity verified
Anthony Kory Jackson, MD
Allopathic & Osteopathic Physicians|Family Medicine · HUTCHINSON, KS · NPI 1366413114
Verified facts
What the public records show
CMS Open Payments records show Anthony Kory Jackson, MD received $582.46 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $195.85 | 33.6% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.95 | 24.0% | 16 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $49.12 | 8.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.31 | 6.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.95 | 5.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.49 | 3.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.11 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.80 | 2.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.31 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.89 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.58 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.35 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.75 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $582.46 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.70 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.52 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $83.46 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.49 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.49 | 9 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
72 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 836 | 191 |
| Lisinopril | Lisinopril | 510 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 97 |
| Sertraline Hcl | Sertraline Hcl | 370 | 72 |
| Omeprazole | Omeprazole | 368 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 349 | 81 |
| Losartan Potassium | Losartan Potassium | 306 | 84 |
| Trazodone Hcl | Trazodone Hcl | 292 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 277 | 64 |
| Potassium Chloride | Potassium Chloride | 274 | 55 |
| Simvastatin | Simvastatin | 261 | 68 |
| Metformin Hcl | Metformin Hcl | 257 | 59 |
| Meloxicam | Meloxicam | 234 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 67 |
| Furosemide | Furosemide | 185 | 40 |
| Montelukast Sodium | Montelukast Sodium | 185 | 37 |
| Gabapentin | Gabapentin | 178 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 162 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 29 |
| Eliquis | Apixaban | 143 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 38 |
| Pregabalin | Pregabalin | 141 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 26 |
| Spironolactone | Spironolactone | 137 | 29 |
| Celecoxib | Celecoxib | 135 | 24 |
| Famotidine | Famotidine | 132 | 32 |
| Baclofen | Baclofen | 128 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 20 |
| Finasteride | Finasteride | 122 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 120 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 29 |
| Tramadol Hcl | Tramadol Hcl | 104 | 22 |
| Buspirone Hcl | Buspirone Hcl | 103 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 26 |
| Metformin Hcl Er | Metformin Hcl | 101 | 21 |
| Donepezil Hcl | Donepezil Hcl | 97 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 15 |
| Atenolol | Atenolol | 91 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 17 |
| Memantine Hcl | Memantine Hcl | 89 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 17 |
| Ozempic | Semaglutide | 79 | 19 |
| Clonazepam | Clonazepam | 78 | 17 |
| Lansoprazole | Lansoprazole | 77 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 14 |
| Myrbetriq | Mirabegron | 72 | 11 |
| Carvedilol | Carvedilol | 71 | 17 |
| Xarelto | Rivaroxaban | 70 | 11 |
| Allopurinol | Allopurinol | 64 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 16 |
| Prednisone | Prednisone | 62 | 41 |
| Trulicity | Dulaglutide | 62 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | suppressed |
| Linzess | Linaclotide | 58 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 14 |
| Methylprednisolone | Methylprednisolone | 54 | 45 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 41 |
| Bupropion Xl | Bupropion Hcl | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 52 | 17 |
| Topiramate | Topiramate | 52 | 12 |
| Farxiga | Dapagliflozin Propanediol | 50 | 11 |
| Jardiance | Empagliflozin | 50 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 12 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 12 |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 33 |
| Bumetanide | Bumetanide | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Azithromycin | Azithromycin | 34 | 24 |
| Gemtesa | Vibegron | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 23 |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 22 |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Primidone | Primidone | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Victoza 2-Pak | Liraglutide | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $582.46 · 44 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, EVENITY, GEMTESA, KISUNLA, OTEZLA, Omnipod, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, Veozah, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error